Zimmer Biomet (NYSE:ZBH) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Zimmer Biomet (NYSE:ZBH) from a buy rating to a hold rating in a research report sent to investors on Sunday.

ZBH has been the subject of a number of other reports. Leerink Partners started coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 price target for the company. Weiss Ratings upgraded shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. UBS Group restated a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Barclays decreased their price target on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday, February 12th. Finally, TD Cowen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $105.95.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $92.78 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $17.96 billion, a P/E ratio of 26.21, a P/E/G ratio of 1.95 and a beta of 0.61. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $108.29. The firm has a 50-day moving average price of $93.80 and a two-hundred day moving average price of $93.15.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter in the prior year, the firm posted $2.31 EPS. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts anticipate that Zimmer Biomet will post 8.39 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

A number of large investors have recently added to or reduced their stakes in ZBH. Brighton Jones LLC purchased a new stake in Zimmer Biomet during the fourth quarter worth about $204,000. Sivia Capital Partners LLC purchased a new stake in Zimmer Biomet during the second quarter worth about $232,000. United Bank increased its holdings in Zimmer Biomet by 10.7% during the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares during the last quarter. Federated Hermes Inc. increased its holdings in Zimmer Biomet by 129.2% during the second quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock worth $194,000 after buying an additional 1,202 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in Zimmer Biomet by 93.6% during the second quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock worth $7,004,000 after buying an additional 37,116 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.